Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: ADMS = MC $107 M-- Cash $160 M--MS Walking P3 Data imminent

No earlier versions found for this Subject.

Return to ADMS = MC $107 M-- Cash $160 M--MS Walking P3 Data imminent

Market Cap $106 m -- Cash $160 M --Parkinson Drug marketed -- Phase 3 readout of MS walking trial imminen (this Quarter) -- Namzaric (alzheimer´s dementia ) starting to receive royalties in may 2020 from Allergan = MASSIVE UNDERPRICED low float gem if phase 3 outcome is positive stock likely exploding to $10++ . STRONG BUY

Adamas Pharma (ADMS)

Marktkap: $107 M
Cash: $160M

Shares Out: 27.7 M

Presentation
ir.adamaspharma.com

"INROADS Phase 3 study of ADS-5102 (GOCOVRI) for walking impairment in patients with multiple sclerosis (MS) enrollment" completed, with topline results expected late Q4 2019

"Adamas Pharmaceuticals is eligible to receive royalties on net sales of Namzaric beginning in May of 2020."